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Abstract

By Rick Kishore Chainani
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Major Director: John R. Grider, Professor, Department of Physiology and Biophysics

The enteric nervous system controls the gut through the release of specific
neurotransmitter and neuromodulators at specific sites such as mucosal secretory cell or smooth
muscle cell. In the present study, we have examined the response to one of these neurohumoral
agents, Neurotensin, in the rat distal colon. Neurotensin is a paracrine and endocrine modulator
of the digestive tract. Even though these effects have been seen in colonic preparations, there are
very few functional studies of the effects of Neurotensin in the rat colon, especially the distal
colon.
In the current study we propose the following hypothesis that Neurotensin will lead to
contractile effect on basal tone and phasic contraction in the distal rat colon and will mediate this
process primarily through the NT1 receptor. This hypothesis is based on evidence from the
mixed action of Neurotensin in other regions of the gut and the more widespread distribution of
the NT1 receptor. We have identified two specific aims to investigate this hypothesis.
Aim 1 is to investigate the role of Neurotensin in tonic contraction and phasic contraction of the
distal rat colon. In this aim, we will expose distal rat colon strips to varying doses of Neurotensin
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and record changes in basal tone and phasic activity. For our second aim, we will investigate the
receptors mediating these responses to Neurotensin. In this aim, we will introduce NT1, NT2,
and nonspecific inhibitors to distal rat colon and observe modulation in Neurotensin effects. We
will also determine the existence of the receptors via Western Blot.
The rat distal colon did respond in a dose-response fashion to varying doses of
Neurotensin, but elicited different effects dependent on the strip preparation. When the mucosa
was intact, circular muscle responded with an inhibitory effect to phasic activity, but there was
little to no change in tonic activity. When the mucosa was removed, the circular muscle
responded to Neurotensin by eliciting an increase in tonic activity, but had no effect on phasic
activity.
The use of SR48692, a specific NT1 receptor inhibitor, showed that the effects that were
observed due to Neurotensin were not mediated through the NT1 receptor. With the use of
SR142948, a non-selective NT1/NT2 inhibitor, the effects of Neurotensin was completely
abolished. This led us to believe that the observed effects were mediated through a Neurotensin
receptor and that receptor is likely the NT2 receptor. This was confirmed by the use of the
specific NT2 receptor antagonist, levocabastine.
The existence of the receptor in rat colon had to be confirmed in order to ensure that the
effects observed were mediated through the NT2 receptor and not from an outside mediator.
Western Blot analysis confirmed the existence of the NT2 receptor within the mucosa, within the
muscle, and within the intact preparation of the distal rat colon. Although these results conflict
with our hypothesis, it provides for an interesting template and avenue of exploration.
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Introduction and Background

1.1 Function of Gut
The gut is a muscular tube that organizes the integrated response to a meal and represents
a complex set of regulated gastrointestinal, secretory, and motor behaviors designed to perform
digestion and absorption of a meal and elimination of wastes. These secretory and motor
behaviors are regulated by neural, hormonal, and paracrine signaling responses. (Pandol 2009).
These processes are aided by smooth muscle that functions in mixing and propelling intestinal
contents through the gut. This propulsion is termed peristalsis.

1.2 Gut Anatomy
The innermost layer of the gut is the mucosa, containing both the epithelial cells
necessary for final digestion and assimilation of the ingested material. The mucosal layer also
possesses glands able to secrete substances into the gut lumen, cells with sensory capabilities,
and the muscularis mucosa, a thin layer of smooth muscle that aids in enhanced contact of the
epithelium with luminal contents as a result of its contractile function. Outside of the mucosal
layer lies the submucosa, another layer of connective tissue that possesses connections to the
vasculature, inflammatory cells, and in some cases, glands. The submucosa contains a neural
plexus, the submucosal plexus which has interconnections within the nervous system of the gut
(enteric nervous system), as well as connections to the autonomic nervous system. This
submucosal plexus is important in controlling the secretory functions of the mucosa through
innervation of the epithelium, and may play a role in the coordination of muscularis mucosae and
10	
  
	
  

muscularis externa activity with secretory activity (Rubin 2009). External to the submucosa is
the circular muscle layer, a layer of smooth muscle cells oriented circumferentially to the central
axis of the gut lumen (Kunze 1999). Continuing outward, the adjacent layer, known as the
myenteric plexus, contains neurons and organized connections among these neurons within the
enteric nervous system, as well as external connections to the autonomic nervous system. This
layer controls the muscular activity of the circular muscle layer beneath it, and the longitudinal
muscle layer above it (Kunze 1999). The longitudinal muscle layer consists of smooth muscle
cells oriented in parallel with the long axis of the lumen. When longitudinal muscle contracts, the
lumen of the gut is dilated at the contraction site and the gut shortened, in contrast to the actions
of the circular muscle. The neural connections provided by the myenteric plexus between the
longitudinal and circular muscle layers coordinate activity to ensure that longitudinal muscle and
circular muscle do not contract at the same location and at the same time (Grider 1998). Beyond
the longitudinal muscle layer there exists the serosa, which serves as an outer containment
membrane for the gut tube. A depiction of these layers are pictured in Figure 1.

1.3 Peristalsis
The intestinal peristaltic reflex consists of ascending and descending phases during which
circular and longitudinal muscle responds in reciprocal fashion. In circular muscle, the
orad contraction is mediated by excitatory motoneurons containing acetylcholine and/or
the tachykinins substance P and neurokinin A , whereas the caudad relaxation is mediated
by inhibitory motoneurons containing vasoactive intestinal peptide (VIP) or pituitary adenylate
cyclase-activating peptide (PACAP) and nitric oxide synthase (NOS). The reflex can be initiated
by circular muscle stretch and mucosal stimulation. (Grider, Kuemmerle 1996). The circular
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muscle layer has its long axis oriented as the circumference around the gut tube whereas the
longitudinal muscle is orientated orad to anal. This organization of muscle layers can be seen in
Figure 1.

1.4 Gut as Agent of Digestion/Absorption/Defense
As food and drink are ingested, regions of the gut play specific roles in the mechanical
and chemical breakdown of food. Mechanically, the muscular tube can collapse upon its
contents, physically compressing them to render the contents into smaller pieces, leading to a
mixture of the various ingested substances. Chemically, the gut releases agents into its lumen,
where mixing with the contents leads to chemical reactions that reduce large molecules such as
starches, proteins, and triglycerides into smaller constitutive pieces such as sugars, peptides, fatty
acids (Nagler-Anderson 2001). The gut itself possesses sensory functions upon its exposure to
contents of a meal. Such sensory cells can feed into a control network that manipulates motility,
secretory, and absorptive behaviors (Kokrashvili 1999) (Egan1998).

1.5 The Enteric Nervous System and Neurotransmitters
Thus, the gut performs many functions and is composed of many cell and tissue
types. The adequate regulation of gut function depends on control of all these different
functions. To maintain control, the gut uses a variety of mechanisms: (1) mucosal paracrine cells
that secrete active agents locally, (2) hormones that are secreted into the blood and affect other
regions of the gut as well as other organ systems and (3) the enteric nervous system and its
connections to the autonomic nervous system. The enteric nervous system controls the gut
through the release of specific neurotransmitter and neuromodulators at specific sites such as
12	
  
	
  

mucosal secretory cell or smooth muscle cell. The number of neurotransmitters has been
estimated to be over 30 different types allowing for a variety of responses depending on the
transmitter released. One characteristic of enteric neurons is that often one neuron can release
more than one neurotransmitter and certain neurotransmitters can be assigned specific
functions. As noted above, excitatory motor neurons which innervate smooth muscle release
acetylcholine and a tachykinin, substance P to cause contraction whereas inhibitory motor
neurons release VIP, PACAP and NO. Sensory neurons release calcitonin gene-related peptide
(CGRP) and Substance P. Most of the other neurotransmitters are contained in interneurons that
connect the motor and sensory neurons together in reflex arc or are contained in other neurons
that innervate the mucosa and smooth muscle as secondary motor neurons. The role of these
other neurotransmitters is much less well known. Many of the neurotransmitters have a dual
presence and function, being contained also in the paracrine and hormonal cells of the
mucosa. Even less is known of the role of these neurohumoral agents. In the present study, we
have examined the response to one of these neurohumoral agents, Neurotensin. (Furness 2008)
(Furness 2004)

1.6 Neurotensin
Neurotensin is a 13 amino acid peptide originally isolated from bovine hypothalamus but
it was subsequently found to be widely distributed in the gastrointestinal tract (Polak 1977).
Neurotensin is a neuromodulator of dopamine transmission and of anterior pituitary hormone
secretion, and exerts potent hypothermic and analgesic effects in the brain. NT has been shown
to modulate dopaminergic transmission in the nigrostriatal and mesocorticolimbic pathways,
thereby implicating this neuropeptide in the pathophysiology of several central nervous system
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disorders, including Parkinson’s disease and schizophrenia (Gendron 2004). In the periphery,
Neurotensin is a paracrine and endocrine modulator of the digestive tract and of the
cardiovascular system of mammals and acts as a growth factor on a variety of normal or cancer
cells. (Vincent 1999). Thus Neurotensin can be a neurotransmitter in the central nervous system
and a paracrine/endocrine agent in the gut. In examining the colon, Neurotensin has been shown
to be involved in the stimulation of colonic motor activity in the canine species (Bardon et al
1984). Augeron also reported that Neurotensin stimulates mucin secretion from human colon
goblet cell line by receptor mediated mechanism (Augeron 1992). Neurotensin has been
shown to relax the rat duodenum, the rat ileum and the guinea-pig proximal colon,
and to contract the rat stomach strip, the guinea- pig taenia coli and the human colon
(Couture et al., 1981). Neurotensin has also been shown to cause inhibition of the spontaneous
contractile activity of the rabbit isolated colon and to produce a biphasic response in the guineapig ileum (Fontaine et al 1985). Even though these effects have been seen in colonic
preparations, there are very few functional studies of the effects of Neurotensin in the rat colon,
especially the distal colon.

1.7 Neurotensin Receptors
The first Neurotensin receptor was cloned in 1990 by Nakanishi and his group and it was
dubbed the NTS1 for the Neurotensin 1 Receptor (referred to as NT1 throughout the paper). This
receptor was found to belong to the G-protein coupled receptor family with the first receptor
antagonist of the receptor, SR48692, developed a year later (Tanaka 1990). Tanaka’s group also
found that the NT1 receptor was found distributed throughout the brain and the intestine of rat
and humans. From the binding data, it was evident that there was a high affinity binding site that
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was insensitive to the putative antagonist Levocabastine, but there was also a low affinity
binding site that was able to be selectively blocked with this drug. Levocabastine is an
antihistamine-1 drug that is devoid of any Neurotensin-like pharmacological properties and
selectively blocks the lower affinity binding site without changing the binding properties of the
higher-affinity sites (Shotte 1986) (Kitabgi 1987). This receptor site was cloned and named the
NTS2 receptor and is also a G-protein coupled receptor that retains a 64% sequence homology to
the NT1 receptor (referred to as NT2 Receptor throughout the paper) (Chalon 1996) (Vincent et
al 1999). This finding allows Levocabastine to be used as an NT2 receptor antagonist. The
putative antagonist SR142948 compound was found to recognize receptors of both species with
even higher affinities than their selective antagonist counterparts, making SR142948 useful as a
broad antagonist of both NT receptors while distinguishing Neurotensin mediated responses
from those mediated by other agents and receptors. (Gully 1997) (Chalon 1996). Xenopus
oocytes transfected with the mouse NT2 receptor respond to NT by induction of a Ca2dependent Cl- current, but the amplitude of the current is 10-100 times smaller than that induced
by Neurotensin on NT1 receptor injected oocytes suggesting that the NT1 receptor would be
more responsible for physiological induced changes (Mazella 1996).

1.8 Neurotensin Receptor Locations
Northern blot analysis has shown that the NT2 receptor mRNA is expressed mostly in the
brain (Chalon 1996) (Mazella 1996) which differs from the NT1 receptor distribution that is
more evenly distributed within the brain and the periphery in mice and rats. A table summarizing
these two receptors is presented in Table 1.
1.9 NT3/Sortilin
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A structurally unrelated receptor, the NT3/Sortilin receptor, is a type I amino acid
receptor with a single transmembrane region that is located intracellularly (Mazella 1998). This
receptor has only been found in human cell types and has 100% homology to the Sortilin protein
found in humans that is involved in the sorting of receptors and is identified by its ability to
interact with receptor-associated protein (Vincent et al 1999). Sortilin is a very promiscuous
receptor and is known to form complexes with many other receptors. In general, it is thought that
Sortilin acts as a clearance receptor to remove these other receptors from the cell surface or to
modulate their activity. It is also generally thought that sortilin, by itself, does not signal and has
no non-clearance function although this notion is just beginning to be challenged. Due to these
characteristics, and the fact that there is no commercially available receptor antagonists of the
NT3 receptor currently, no experiments were conducted with the NT3 receptor (Nykjaer 2012)
(Mazella 2001).

1.10 Hypothesis and Specific Aims
In the current study we propose the following hypothesis that Neurotensin will lead to
contractile effect on basal tone and phasic contraction in the distal rat colon and will mediate this
process primarily through the NT1 receptor. This hypothesis is based on evidence from the
mixed action of Neurotensin in other regions of the gut and the more widespread distribution of
the NT1 receptor. We have identified two specific aims to investigate this hypothesis.
Aim 1 is to investigate the role of Neurotensin in tonic contraction and phasic contraction
of the distal rat colon. In this aim, we will expose distal rat colon strips to varying doses of
Neurotensin and record changes in basal tone and phasic activity.
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For our second aim, we will investigate the receptors mediating these responses to
Neurotensin. In this aim, we will introduce NT1, NT2, and nonspecific inhibitors to distal rat
colon and observe modulation in Neurotensin effects. We will also determine the existence of the
receptors via Western Blot.
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Figure 1: The anatomical organization of the wall of the gastrointestinal tract. Adapted from
Furness and Costa (1987), The Enteric Nervous System
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Table 1: Summary of Neurotensin Receptor Subtypes. Adapted from Hermans and Malateaux
(1998), Mechanism of regulation of Neurotensin receptors
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Materials and Methods
2.1 Animal Preparation
Rats were euthanized by CO2 asphyxiation under protocols approved by the Institutional
Animal Care and Use Committee of VCU. The colon was dissected out, emptied of contents and
placed in a warmed (37°C) oxygenated Krebs solution of the following composition (in mM):
118 NaCl, 4.75 KCl, 1.19 KH2PO4, 1.2 MgSO4, 2.54 CaCl2, 25 NaHCO3, 11 mM glucose (pH
7.4). 2-3 cm long sections of distal colon and proximal colon were removed and pinned in a Petri
dish warmed by circulating (37°C) water and filled with warmed (37°C) Krebs solution. The
resultant section of colon was freed of excess fat and mesenteric attachments and held in
oxygenated Krebs buffer until use for tension recording or molecular assay. Normally the time
from removal to use in experimental protocol did not exceed 30 minutes. A muscle strip was
prepared from the colonic segment by opening the segment along the mesenteric attachment by
sharp dissection and pinning out flat in the Petri dish with the mucosal side uppermost. Care was
taken to maintain knowledge of the orientation of circular and longitudinal axis of the tissue for
subsequent strip preparation.

2.2 Strip Preparation
Strips destined for recordings of contractile behavior were tied at both ends with surgical
silk – on one end a simple loop for attachment to a glass hook, the other end to a length of silk
tied to a brass ring. Some strips were left intact while others had their mucosa gently scraped off.
In order to differentiate between the longitudinal muscle and the circular muscle without directly
removing them from the strip in order to preserve muscle integrity, strips were tied and hung in
an orientation where force transduction was only in the direction of the desired muscle type. To
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measure circular muscle contraction, the strip was orientated such that the direction circular
muscle runs along the colon would be placed vertically within the bath so the transducer would
only respond to contractions in that particular direction. The same was performed with
longitudinal muscle measurements. The strip was then placed in a vertical orientation with the
loop secured to a glass hook and the brass ring to a FT-03C Force Transducer (Grass
Instruments, East Warwick, RI). An organ bath (Radnoti, Monrovia, CA) was raised to submerge
the strip in 5 mL of continuously oxygenated and warmed Krebs solution. Force recordings were
amplified by an Octal Bridge Amplifier (AD Instruments, Colorado Springs, CO), relayed to a
Powerlab 8/35 with Grass Adaptor Unit and displayed by a PC running LabChart Pro7 (AD
Instruments, Colorado Springs, CO). Force was recorded in grams and raw value data was able
to be retrieved and exported into Microsoft Excel for further analysis.
Strips destined for molecular assay were treated as those intended for recordings until the
pinning procedure. Selected distal colon strips had their mucosa removed and were preserved but
separated into different tubes. A whole tissue strip was also isolated and kept in a microcentrifuge tube. This same process was repeated for proximal colon strips as well. Tissue
samples were placed into TPER (Tissue Protein Extraction Reagent, Pierce, and Rockford, IL)
lysis buffer. Into each vehicle, a protease/phosphatase cocktail (100 g/mL PMSF, 10 g/mL
leupeptin, 30 mM sodium fluoride and 3 mM sodium vanadate) was added at a concentration of
2 µL/mL. Tissue was homogenized and solubilized in the above solutions. Following
centrifugation at 14000 g for 15 min at 4°C, the supernatant was removed and prepared for
Western Blot Analysis.
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2.3 Force Measurement
Force experiments were conducted in the following manner. Following hanging of the
strip and submersion in the organ bath filled with warm oxygenated Krebs solution, strips were
subjected to 1 gram of pre-tension. Strips were allowed to equilibrate for no less than 45 minutes
during which the strips were washed at 15 min intervals before experiments were conducted and
data collected. Exposure to Neurotensin, antagonists, and KCl occurred within the organ bath.
Concentrations were determined from preliminary experiments or from published articles and
were in agreement with current literature and are noted in the results.
Following an experiment, strip data were reviewed and analyzed from within the
LabChart 7 software suite. Experiments were designed to compare treatment to control
conditions with each strips serving as its own control. Paired t-tests were conducted in Prism 6
(GraphPad Software, La Jolla, CA), and significance set at P < 0.05. The dose-response curve
obtained was subject to ANOVA via Prism.

2.4 Data Analysis
Contractile data was viewed from several perspectives as to determine the dose-response
effect of Neurotensin and to characterize the effect of Neurotensin on the distal rat colon in the
presence of the NT1 and NT2 receptor antagonists: changes in phasic contraction and changes in
tonic contraction (basal tone) were noted. Measurements were taken over a course of 90 seconds
prior to administration of any drug and 90 seconds after administration of a drug (or in the case
of measuring change in basal tone, measurement at plateau within 90 seconds). After every
application of drug, a minimum of an hour washout period was used with 15 minutes in between
washes of warmed oxygenated Krebs in concordance with previous literature obtained in other
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regions of the small and large intestine in order to minimize receptor desensitization (Mule
1996). Our preliminary studies (data not shown) confirmed that this was necessary to obtain
reproducible contractions to Neurotensin and to avoid desensitization. Once raw values were
retrieved, calculations of percent change and statistical analysis were performed in Prism 6
(GraphPad Software, La Jolla, CA).
Dose Response curves were analyzed via one sample one tail t-tests (P<0.05 for
significance) and reported as percent change +/- Standard Error of the Mean. Inhibitor
experiments were analyzed via two tailed t-tests (P<0.05 for significance).

2.5 Phasic Contraction
Phasic contraction was measured as the average difference between the cyclic maxima
and minima in the selected cycles. For the studied 90 second interval, the difference was
calculated between the peak of a contraction and minima of contraction and these values were
averaged over the 90 second interval. Such measurements were made in multiple strips from
multiple animals and paired t-tests conducted to determine if a difference was significant.

2.6 Tonic Contraction
Tonic contraction was determined by measuring the change in basal tone of the muscle
strip and was accomplished by calculating the mean of the basal tonic level upon which phasic
contractions were superimposed within the studied 90 second intervals. The intent of the
experiment was to observe percent changes in basal tone, measured before and after treatment
with Neurotensin in the presence or absence of receptor antagonists.
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2.7 Western Blot Analysis
To determine the amount and molecular size of proteins present in a sample, Western
Blotting was used. Cell lysates were prepared and electrophoresed on a 1.5 mm thick
12% Tris/glycine SDS-polyacrylamide gel containing 0.1% SDS (?) for 1.5 hours at 110V in 1X
SDS-PAGE running buffer (20mM Tris-glycine pH 8.3, 100mM NaCl, 70mM EDTA, 2% (w/v)
SDS). Proteins were then transferred to a Nitrocellulose transfer membrane (BioRad, Hercules
CA) overnight in 1X transfer buffer (20mM Tris-HCl pH 7.9, 100mM NaCl, 70mM EDTA, 20%
MeOH).
Following transfer, membranes were washed three times in TBS (10 mM Tris HCl pH
7.6, 150 mM NaCl) supplemented with 0.5% Tween 20 for 15 minutes each then incubated in
blocking buffer (5% non-fat dried milk in TBS-T) for one hour on a shaker before incubating
overnight at 4˚C in primary antibody recognizing a specific target protein (Table 3) diluted in
blocking buffer. Membranes were then washed as before in TBS-T and bound antibody was
detected by 1 hour incubation at room temperature with the appropriate IRDye secondary
antibody (Table 2) diluted in blocking buffer. The interaction of the primary and secondary
antibodies was detected and imaged using ODYSSEY Infrared Imaging System (LI-COR
Biotechnology, Lincoln NE)

Primary Antibody

Dilution

Secondary Antibody

NT1 Monoclonal: sc-7596

1:1,000

Anti-mouse

NT2 Polyclonal sc-6243

1:1,000

Anti-rabbit

Table #2. Antibodies for Western Blot. All antibodies were obtained from SigmaAldrich (St. Louis, MO).
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Results

3.1 Contractile Response in Circular and Longitudinal Muscle
Sample traces are presented to demonstrate the variety of contraction waveforms and
responses to Neurotensin. Contractions may exhibit phasic activity superimposed upon the
described waveforms. N is designated as the number of unique strips used. Strips of the distal rat
colon were exposed to Neurotensin at concentrations of 10−9 M, 10−8 M, 10−7 M, and 10−6 M in
order to produce a dose-response curve. Longitudinal and circular muscle strips were
differentiated as described in the methods section. Because circular muscle strips and
longitudinal muscle strips responded in the same manner to varying doses of Neurotensin and as
the circular muscle is the dominant force to propulsive activity within the gut as cited in the
introduction, circular muscle was used for the rest of the experiments. When the mucosa is intact,
muscular strips exposed to Neurotensin responded with an inhibitory effect to its phasic activity.
When the mucosa is removed, there tended to not be a major change in phasic activity due to
Neurotensin, but an increase in basal tone (tonic activity) was observed regardless if the strip was
longitudinal or circular muscle. An example of the similarities in response to Neurotensin in
circular and longitudinal muscle strips of distal rat colon with the mucosa intact is shown in
Figure #2.
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Figure #2: Circular and Longitudinal Muscle Tracings with Mucosa Intact

The first tracing is a sample tracing of Circular muscle with the mucosa intact from the
distal rat colon and the second tracing is longitudinal muscle also with mucosa intact from the
distal rat colon. Dotted vertical line indicates addition of 10−6 M Neurotensin followed by the
inhibitory response of the muscle strip. The Y-axis is in grams force and the X-axis is time in 20
second intervals.
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3.2 Differences in Mucosa Intact and Mucosa Removed
From here, all muscle strips are of circular muscle unless otherwise noted. Circular muscle
with mucosa intact tended to have more pronounced and frequent phasic activity as opposed to
strips with their mucosa removed. Likewise, strips with their mucosa intact tended to respond to
Neurotensin by attenuating phasic activity but having a minimal effect on tonic activity, but
strips with their mucosa removed tended to not have their phasic activity affected in response to
Neurotensin but had an increase in tonic contractile activity. An example of the difference
between the effect of Neurotensin on circular muscle tissue with the mucosa intact and their
mucosa removed is shown in Figure #3. Table #3 summarizes this pattern as well and data
analysis on this finding follows the tracings.

Phasic Contraction

Tonic Contraction

Circular Muscle (+) Mucosa

↓

-

Circular Muscle (-) Mucosa

-

↑

Table #3. Summary of Neurotensin Effects. Summary of rat distal colon preparations’
with (+) and without (-) mucosa, responses to Neurotensin
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Figure #3: Mucosa Intact Versus Mucosa Removed Muscle Tracings
The first tracing is a sample tracing of Circular muscle with the mucosa intact from the
distal rat colon and the second tracing is Circular muscle with mucosa removed from the distal
rat colon. Dotted vertical line indicates addition of 10−6 M Neurotensin followed by the
inhibitory response of the muscle strip in the mucosa intact strip and the contractile response in
the mucosa removed strip.	
  The Y-axis is in grams force and the X-axis is time in 20 second
intervals.
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3.3 Data Analysis of Dose Response of Neurotensin Measuring Phasic Change
The responses of varying doses of Neurotensin were observed in the distal rat colon in
two preparations. A one sample t-test was performed (P<0.05 for significance) for all doseresponse graphs. All strips serve as their own individual controls for the experimental treatments
and all statistical tests are suitably conducted on repeated measurements. Strips were incubated
in Neurotensin for no more than two minutes and then washed out with warm Krebs solution
because preliminary studies demonstrated a tendency of Neurotensin to cause desensitization
with prolonged exposure. This procedure was repeated with strips with their mucosa intact as
mentioned in detail in the Methods section. For experiments performed with their mucosa intact,
inhibitory responses were a mean of -2.63% ± 6.12% (n=7, 2 rats) at 10 M concentration of
−9

Neurotensin, -13.17% ± 4.78% (n=8, 2 rats) at 10 8 M concentration of Neurotensin, -22.25% ±
−

5.16% (n=28, 5 rats) at 10 7 M concentration of Neurotensin, and -32.34% ± 4.87% (n=44, 9 rats)
−

at 10 6 M concentration of Neurotensin (Figure 4). The Neurotensin doses ranging from 10 M to
−

−6

10 8 M were found to be statistically significant (P<0.05).
−

For experiments performed with their mucosa removed, percent change of phasic activity
was a mean of -0.67% ± 2.63% (n=8, 2 rats) at 10 9 M concentration of Neurotensin, -4.69% ±
−

1.66% (n=8, 2 rats) at 10 M concentration of Neurotensin, -3.84% ± 2.83 (n=28, 5 rats) at 10 M
−8

−7

concentration of Neurotensin, and -7.65% ± 2.59% (n=44, 9 rats) at 10 M concentration of
−6

Neurotensin (Figure 5). Although all responses were minimal and not likely to be biologically
significant, the Neurotensin doses 10 M and 10 M were found to be statistically significant
−8

−6

(P<0.05).
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Figure #4: Dose-Response of Phasic Changes in response to Neurotensin with Mucosa
Intact
Sample size for 10 M Neurotensin (n=7, 2 rats), 10 M Neurotensin (n=8, 2 rats), at 10 M
−9

−8

−7

Neurotensin (n=28, 5 rats), and 10 M Neurotensin (n=44, 9 rats)
−6
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Figure #5: Dose-Response of Phasic Changes in response to Neurotensin with Mucosa
Removed
Sample size for 10 M Neurotensin (n=8, 2 rats), 10 M Neurotensin (n=8, 2 rats), at 10 M
−9

−8

−7

Neurotensin (n=28, 5 rats), and 10 M Neurotensin (n=44, 9 rats)
−6
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3.4 Dose Response of Neurotensin Measuring Tonic Change
While phasic changes were noted in response to Neurotensin as described above, strips
also exhibited changes in their basal tone either in addition to or excluding changes in phasic
activity. Similar to the previous experiment, the contractile responses of distal rat colon to
varying doses of Neurotensin, specifically the changes in basal tone, were measured. The strips
were exposed to Neurotensin for no more than 2 minutes as indicated in the methods section. For
experiments performed with their mucosa intact, percent change in basal tone was a mean of 1.04% ± 1.22% (n=8, 2 rats) at 10−9 M concentration of Neurotensin, -6.73% ± 1.51% (n=8, 2
rats) at 10−8 M concentration of Neurotensin, -8.89% ± 1.87% (n=28, 5 rats) at 10−7 M
concentration of Neurotensin, and -6.03% ± 2.25% (n=44, 9 rats) at 10−6 M concentration of
Neurotensin (Figure 6). These force measurements were found to be statistically significant
(P<0.05) for doses ranging from 10−6 M to 10−8 M according to a one sample t-test. It is
noteworthy that for these strips there was an inhibition of tone which paralleled the effect of
Neurotensin on phasic activity in these strips. Even though reaching statistical significance, the
response was however relatively small compared to the inhibition of phasic activity.
For experiments performed with their mucosa removed, percent change of tonic
contraction was a mean of -0.79% ± 0.32% (n=8, 2 rats) at 10−9 M concentration of
Neurotensin, -0.95 ± 0.48% (n=8, 2 rats) at 10−8 M concentration of Neurotensin, 0.97% ± 2.11
(n=28, 5 rats) at 10−7 M concentration of Neurotensin, and 12.90% ± 3.28% (n=44, 9 rats) at 10−6
M concentration of Neurotensin (Figure 7). According to a one sample t-test, the 10−6 M dose of
Neurotensin was statistically significant (P<0.05).
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Figure #6: Dose-Response of Tonic Changes in response to Neurotensin with Mucosa Intact
Sample size for 10−9 M Neurotensin (n=8, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7
M Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats)
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Figure #7: Dose-Response of Tonic Changes in response to Neurotensin with Mucosa
Removed
Sample size for 10−9 M Neurotensin (n=8, 2 rats), 10−8 M Neurotensin (n=8, 2 rats), at 10−7
M Neurotensin (n=28, 5 rats), and 10−6 M Neurotensin (n=44, 9 rats)
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3.5 Effects of NT1 Receptor Antagonism
The effects of Neurotensin has been shown to be mediated by the NT1 and NT2 receptors in
a variety of other tissues, but the role of these receptors in the distal rat colon have not been
thoroughly characterized.. All strips were from distal rat colon and were subjected to 10−6 M
concentration of SR 48692, a well-known selective inhibitor of the NT1 receptor, for 10 minutes
prior to incubation with 10−6 M Neurotensin in a variety of strip preparations to observe the
changes in phasic or tonic activity of these muscle strips in response to Neurotensin. A
concentration of 10−6 M of SR 48692 and 10 minute exposure was used in concordance with
previous literature utilizing similar methods of strip preparation. Addition of SR 48692 alone had
no effect on tonic or phasic activity of the muscle strips.
We first measured percent changes in phasic activity due to treatment. Incubation with
10−6 M Neurotensin with the mucosa intact caused a mean percent change of -37.84% ±
11.41%(n=8, 4 rats) and incubation of Neurotensin and the inhibitor lead to a mean percent
change of -36.26% ± 10.72% (n=8, 4 rats). The same incubation with the mucosa removed
caused a mean percent change of -6.17% ± 4.10 (n=8, 4 rats) while incubation of the inhibitor
with Neurotensin caused a mean percent change of -5.13% ± 2.44% (n=8, 4 rats). There were no
statistically significant changes to phasic contraction with the inhibitor with mucosa intact or
removed (all P > 0.05, n=8 from 4 animals). Data was analyzed by a paired two-tailed t-test
(P<0.05 to achieve significance). Results are summarized in Figure 8 and 9.
Next, we repeated the above experiment but measured percent changes in tonic
contraction. Incubation with 10−6 M Neurotensin with the mucosa intact caused a mean percent
change of -5.47% ± 2.10% (n=8, 4 rats) and incubation of Neurotensin and the inhibitor lead to a
mean percent change of -4.90% ± 2.58% (n=8, 4 rats) . The same incubation with the mucosa
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removed caused a mean percent change of 4.22% ± 1.65% (n=8, 4 rats) while incubation of the
inhibitor with Neurotensin caused a mean percent change of 4.88% ± 2.19% (n=8, 4 rats). There
were no statistically significant changes to tonic contraction with the inhibitor in mucosa intact
or removed (all P > 0.05, n=8 from 4 animals). Data was analyzed by a paired two-tailed t-test
(P<0.05 to achieve significance). Results are summarized in Figure 10 and 11.
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Figure #8: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Phasic
Contraction with Mucosa Intact
Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M
SR48692 inhibitor (n=8, 4 rats)
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Figure #9: Effect of 10 M Neurotensin and NT1 Selective Receptor Antagonist on Phasic
−6

Contraction with Mucosa Removed
Sample size for 10 M Neurotensin (n=8, 4 rats) and 10 M Neurotensin + 10 M SR48692
−6

−6

−6

inhibitor (n=8, 4 rats)
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Figure #10: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Tonic
Contraction with Mucosa Intact
Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M
SR48692 inhibitor (n=8, 4 rats)
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Figure #11: Effect of 10−6 M Neurotensin and NT1 Selective Receptor Antagonist on Tonic
Contraction with Mucosa Removed
Sample size for 10−6 M Neurotensin (n=8, 4 rats) and 10−6 M Neurotensin + 10−6 M
SR48692 inhibitor (n=8, 4 rats)
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3.6 Effects of Nonselective Receptor Antagonism
Since the NT1 antagonist did not significantly affect the response to Neurotensin, the
effect of a non-selective Neurotensin receptor antagonist, SR-142,948, was next tested on the
effect of Neurotensin on the muscle strips. All strips were from distal rat colon and were
subjected to 10−6 M concentration of SR-142,948, a non-peptide and non-selective inhibitor of
the Neurotensin receptors for 10 minutes prior to incubation with 10−7 M Neurotensin and 10−6 M
Neurotensin in a variety of strip preparations to observe the changes in phasic or tonic activity of
these muscle strips in response to Neurotensin. The nonselective antagonist added to the strips
alone had no effect on the basal tone or phasic contractions by itself. The 10−6 M concentration
of SR-142,948 was used in concordance with literature performing similar experiments (Croci et
al 1999). We first measured percent changes in phasic activity due to treatment. Incubation with
10−7 M and 10−6 M Neurotensin with the mucosa intact caused a mean percent change of -31.65%
± 10.29% (n=12, 4 animals) and -43.43% ± 10.76% (n=12, 4 animals) respectively. Incubation of
10−7 M Neurotensin and the inhibitor lead to a mean percent change of -1.41% ± 3.53% (n=12, 4
animals). After, 10−6 M Neurotensin was added to the bath the mean percent change of phasic
contraction was -4.59% ± 3.91% (n=12, 4 animals). The same incubation procedure with the
mucosa removed caused a mean percent change of -3.78% ± 3.21 (n=12, 4 animals) with 10−7 M
Neurotensin and -9.66% ± 6.24% (n=12, 4 animals) with 10−6 M Neurotensin. Incubation of the
inhibitor and 10−7 M Neurotensin caused a mean percent change of -1.05% ± 1.38% (n=12, 4
animals). After 10−6 M Neurotensin was added to the bath the mean percent change of phasic
contraction was -0.91% ± 1.14% (n=12, 4 animals). The strips incubated in the 10−7 M
Neurotensin treatment and the strips incubated in the 10−7 M Neurotensin treatment with the
inhibitor were significantly different when the mucosa was intact. Likewise, The strips incubated
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in the 10−6 M Neurotensin treatment and the strips incubated in the 10−6 M Neurotensin treatment
with the inhibitor were significantly different when the mucosa was intact(P < 0.05, n=12 from 4
animals). Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve significance). There
was no significant difference with the inhibitor when the mucosa was removed. Results are
summarized in Figure 12 and 13.
We repeated the above experiment but measured percent changes in tonic contraction
instead of phasic contraction. Incubation with 10−7 M and 10−6 M Neurotensin with the mucosa
intact caused a mean percent change of -12.00% ± 3.72% (n=12, 4 animals) and -17.60% ±
6.56% (n=12, 4 animals) respectively. Incubation of 10−7 M Neurotensin and the inhibitor lead to
a mean percent change of 1.08% ± 1.25% (n=12, 4 animals). After 2 minutes, 10−6 M
Neurotensin was added to the bath without washing out the bath and the mean percent change of
phasic contraction was 3.25% ± 1.84% (n=12, 4 animals). The same incubation procedure with
the mucosa removed caused a mean percent change of 2.41% ± 4.59(n=12, 4 animals) with 10−7
M Neurotensin and 27.29% ± 8.77% (n=12, 4 animals) with 10−6 M Neurotensin. Incubation of
the inhibitor and 10−7 M Neurotensin caused a mean percent change of 0.58% ± 0.56% (n=12, 4
animals). After 2 minutes, 10−6 M Neurotensin was added to the bath without washing out the
bath and the mean percent change of tonic contraction was 0.46% ± 0.97% (n=12, 4 animals).
The strips incubated in the Neurotensin treatment and the strips incubated in the Neurotensin
treatment with the inhibitor were significantly different when the mucosa was intact (P < 0.05,
n=12 from 4 animals). When the mucosa was removed, the data was only significant for the 10−6
M Neurotensin and the inhibitor (P < 0.05, n=12 from 4 animals). Data was analyzed by a paired
two-tailed t-test (P<0.05 to achieve significance). Results are summarized in Figure 14 and 15
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Figure #12: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist
on Phasic Contraction with Mucosa Intact
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats),
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin +
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).
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Figure #13: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist
on Phasic Contraction with Mucosa Removed
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats),
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin +
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).
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Figure #14: Effect of 10−7 M, 10−6 M Neurotensin, and Non-selective Receptor Antagonist
on Tonic Contraction with Mucosa Intact
Sample size for 10−7 M Neurotensin (n=12, 4 rats), 10−6 M Neurotensin (n=12, 4 rats),
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats), and 10−6 M Neurotensin +
10−7 M Neurotensin + 10−6 M SR-142,948 inhibitor (n=12, 4 rats).
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Figure #15: Effect of 10 M, 10 M Neurotensin, and Non-selective Receptor Antagonist on
−7

−6

Tonic Contraction with Mucosa Removed
Sample size for 10 M Neurotensin (n=12, 4 rats), 10 M Neurotensin (n=12, 4 rats), 10
−7

−6

−7

M Neurotensin + 10 M SR-142,948 inhibitor (n=12, 4 rats), and 10 M Neurotensin + 10 M
−6

−6

−7

Neurotensin + 10 M SR-142,948 inhibitor (n=12, 4 rats).
−6
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3.7 Effects of NT2 Receptor Antagonism
Exposure of muscle strips to a selective NT2 antagonist in the same manner as the
previous experiment was performed next. Since the NT1 antagonist had no effect on the response
to Neurotensin and the nonselective antagonist was effective, we used this NT2 antagonist to
confirm that the effects of Neurotensin were mediated by the NT2 receptors. All strips were from
distal rat colon and were subjected to 10−5 M concentration of Levocabastine, a well-known
potent and selective inhibitor of the NT2 receptor for 10 minutes prior to incubation with 10−6 M
Neurotensin in a variety of strip preparations to observe the changes in phasic or tonic activity of
these muscle strips in response to Neurotensin. The NT2 receptor antagonist added to the strips
alone had no effect on basal tone or phasic activity by itself. The 10−5 M concentration of
Levocabastine was used in concordance with literature performing similar experiments in muscle
strips (Croci et all 1999). We first measured percent changes in phasic activity due to treatment.
Incubation with 10−6 M Neurotensin with the mucosa intact caused a mean percent change of 31.73% ± 7.70% (n=16, 6 rats) and incubation of Neurotensin and the inhibitor lead to a mean
percent change of -9.37% ± 4.14% (n=16, 6 rats). The same incubation with the mucosa removed
caused a mean percent change of -3.38% ± 1.02 (n=16, 6 rats) while incubation of the inhibitor
with Neurotensin caused a mean percent change of 0.20% ± 0.70% (n=16, 6 rats). The strips
incubated in the Neurotensin treatment and the strips incubated in the Neurotensin treatment with
the inhibitor were significantly different when the mucosa was both intact and removed (P <
0.05, n=16 from 6 animals). Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve
significance). Results are summarized in Figure 16 and 17.
We repeated the above experiment but measured percent changes in tonic contraction
instead of phasic contraction. Incubation with 10−6 M Neurotensin with the mucosa intact caused
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a mean percent change of -0.13% ± 1.16% (n=16, 6 rats) and incubation of Neurotensin and the
inhibitor lead to a mean percent change of -1.85% ± 0.66% (n=16, 6 rats) . The same incubation
with the mucosa removed caused a mean percent change of 13.00% ± 3.83 (n=16, 6 rats) while
incubation of the inhibitor with Neurotensin caused a mean percent change of -2.54% ± 0.60%
(n=16, 6 rats). With the mucosa intact, there was no significant difference between the
Neurotensin treated strips and the Neurotensin with NT2 inhibitor strips (P > 0.05, n=16 from 6
animals). However, when the mucosa was removed, there was a significant difference between
the Neurotensin treated strips and the Neurotensin with NT2 inhibitor strips (P < 0.05, n=16 from
6 animals). The Data was analyzed by a paired two-tailed t-test (P<0.05 to achieve significance).
Results are summarized in Figure 18 and 19.
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Figure #16: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Phasic
Contraction with Mucosa Intact
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M
Levocabastine inhibitor (n=16, 6 rats)
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Figure #17: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Phasic
Contraction with Mucosa Removed
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M
Levocabastine inhibitor (n=16, 6 rats)
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Figure #18: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Tonic
Contraction with Mucosa Intact
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M
Levocabastine inhibitor (n=16, 6 rats)
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Figure #19: Effect of 10−6 M Neurotensin and NT2 Selective Receptor Antagonist on Tonic
Contraction with Mucosa Removed
Sample size for 10−6 M Neurotensin (n=16, 6 rats) and 10−6 M Neurotensin + 10−5 M
Levocabastine inhibitor (n=16, 6 rats)
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3.8 Existence of NT2 Receptor
To determine the existence of the NT1 and NT2 receptor within the distal rat colon and to
see how this compares in the proximal rat colon, where previous published data have shown
these receptors to be expressed, a western blot was performed on cell lysates from 6 different
strip preparations: intact proximal rat colon, the mucosa of the proximal rat colon, proximal rat
colon with the mucosa removed, intact distal rat colon, the mucosa of the distal rat colon, and
distal rat colon with the mucosa removed. Figure 20 shows the clear existence of the NT2
receptor across all strip preparations. The existence of the NT1 receptor is also shown to be in all
strip preparations.
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Figure #20: Western Blot for NT2 Receptor in Rat Proximal and Distal Colon
NT2 Receptor expression in Rat proximal and Rat distal colon were measured in varying
tissue preparations. Lane 1 represents solely the mucosa of rat proximal colon. Lane 2 represents
solely the muscle strip with the mucosa removed of the rat proximal colon. Lane 3 represents the
full intact strip of rat proximal colon. Lane 4 represents solely the mucosa of rat distal colon.
Lane 5 represents solely the muscle strip with the mucosa removed of the rat distal colon. Lane 6
represents the full intact strip of rat distal colon.
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Discussion	
  

4.1 Importance of Circular Muscle
It was evident early on throughout the experiments that circular muscle and longitudinal
muscle tended to retain almost identical waveform characteristics. This makes sense logically
from a physiological perspective since circular muscle causes the intestinal contents to propel
further down the gastrointestinal tract whereas longitudinal muscle causes the intestine to bunch
together. Seeing as longitudinal muscle strips and circular muscle strips responded the same to
Neurotensin and circular muscle is more vital in performing the main function of the gut, circular
muscle became the focus of our study. The similarities in waveforms and similarities in response
to Neurotensin is evident in Figure 2.

4.2 Dose Response
As mentioned in the introduction, the enteric nervous system works to control the gut
through the release of specific neurotransmitters at specific sites such as mucosal secretory cells.
While neurotransmitters may be released from these sites, they may function by binding to
receptors at any of the multitude of layers of the gut. Thus, it was of our labs interest to examine
how Neurotensin was to affect the muscle with or without the presence of the mucosa. A dose
response relationship was used to see how different levels of Neurotensin concentration would
affect the various muscle conditions.
Phasic changes within muscle strips with the mucosa intact in response to Neurotensin
lead to a clear trend in inhibition. As the dose of Neurotensin increased, the percent decrease in
phasic contraction increased. It is possible that the mucosa in the distal colon contains secretory
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or enteroendocrine cells that respond to Neurotensin by releasing inhibitory neurotransmitters, or
paracrine agents. It would not be surprising if Neurotensin itself binds to receptors on the mucosa
or on the muscle fiber itself to directly inhibit phasic activity. For future studies, it would be
useful to observe the same effects of Neurotensin without neural input by using tetrodotoxin
(TTX). TTX acts to inhibit any affected nerve cells from firing by blocking the sodium channels
which mediate the action potential. When the mucosa was removed, concentrations of 10 8 M and
−

10−6 M proved to be statistically significant, but in observing the trends, the responses were
minimal and virtually identical. With the highest concentration leading to a 7.65% decrease, the
changes looked to be biologically irrelevant.
While there were changes in the phasic activity of the waveforms, Neurotensin also
elicited changes in basal tone, also termed tonic activity. We analyzed tonic changes in order to
see if Neurotensin’s effects on muscle strips were limited to changes in phasic activity. With the
mucosa intact, concentrations of Neurotensin at 10−8 M, 10−7 M, 10−6 M were all found to be
significantly different from baseline, but just as in the previous graph, the changes were minimal
and biologically irrelevant as can be seen in the trend on the graph in Figure 3. When the mucosa
was removed, it took a 10−6 M concentration to elicit a significant response. This increase in
basal tone when the mucosa was removed was indicative of the responses seen visually in figure
3. The biphasic shape was very common in other studies as well (Ohashi 1994) (Fontaine et al
1985) that used similar preparations. This reinforces our earlier thoughts of the mucosa having
some inhibitory neuropeptides released in response to Neurotensin. Since there is a contractile
effect when the mucosa removed (albeit a tonic contraction), it would indicate that there would
be receptors on the muscle itself and this response leads to either a direct increase in contraction
or a release of excitatory neurotransmitters. A summary of these results is seen in table 3. In
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every case, a 10 6 M dose of Neurotensin elicited the best response and would be the dose used in
−

every receptor study to follow. We did not try higher concentrations of Neurotensin because this
would be too expensive given the amount necessary for use in our 5 ml tissue baths.

4.3 NT1 Receptor
As noted in the introduction, previous studies indicate that the NT1 receptor is more
responsive and has a higher affinity to Neurotensin than the NT2 receptor (Mazzella 1999). The
NT2 receptor retains a 10-fold lower affinity to Neurotensin than the NT1 receptor (Schotte et al
1986). We decided to identify which receptors mediated the responses in our dose response
curves. First we used a NT1 receptor, SR 48692, to determine if the phasic and tonic changes we
observed in the different muscle conditions would be affected by inhibition of the NT1 receptor.
Our results show that there was not a significant difference in the Neurotensin induced changes
in phasic and tonic activity between those treated with 10−6 M Neurotensin and 10−6 M
Neurotensin with the inhibitor. This would indicate that the effects observed were not mediated
through the NT1 receptor. Although previous studies were not performed in the rat distal colon,
this was contrary to what was seen in proximal colon, the brain, and other regions of the gut in
many animals (Pettibone 2002). This would indicate that the rat colon is unique in its response.
Our studies with the NT1 antagonist alone also showed no effect on the basal phasic activity or
tonic activity. This suggests that there is no release of endogenous NT acting through NT1
receptors to modulate activity in the absence of stimulation.
As this is a physiological functional study, future studies should be done to examine
whether this is due to a difference in the ratio of Neurotensin receptors or if this is due to
differences in downstream mediators of the receptors. Pharmacological and biochemical studies
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have indicated that the NT1 receptor is coupled to cGMP, cAMP, and inositol phosphate
signaling cascades (Hermans 1998) (Vincent et al 1999). It would be helpful to see if this
mechanism is the same mechanism is responsible for the physiological responses observed in the
distal rat colon.

4.4 Non-selective Inhibitor
A non-selective inhibitor was used in separate studies following the completion of the
studies with the NT1 selective inhibitor in order to elucidate if Neurotensin effects could be
inhibited at all by blockade of NT receptors. The changes in phasic contraction with the mucosa
intact and removed due to Neurotensin were observed to be almost completely inhibited with the
introduction of the nonselective inhibitor. Phasic contraction when the mucosa was removed did
not show significant difference but just like in the previous experiments, phasic contractions with
the mucosa removed produced little to no change in the first place so it is not unreasonable to not
see much change when incubated with the inhibitor. Tonic contraction with the mucosa removed
only showed significance when the Neurotensin dose of 10−6 M was used. This is also not too
surprising since a 10−6 M dose was required to elicit a significant response in tonic contraction
with the mucosa removed in the first place. When the nonselective antagonist was tested against
the 10−6 dose of Neurotensin, it caused a significant inhibition. Since this antagonist does not
distinguish between NT1 and NT2 receptors and since the selective NT1 receptor antagonist had
no effect, this suggested that the NT2 receptor could be the main mediator of the response. This
idea was tested in the next set of experiments. It should be noted that the non-selective antagonist
had no effect on basal phasic activity or basal tone when added alone. As described above, we
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interpret this to mean that there is no basal, unstimulated release of Neurotensin that is modifying
the basal contractile activity of the colonic muscle.

4.5 NT2 Receptor
From these results it would seem that the NT2 receptor is the main mediator in the effects
elicited by Neurotensin, but we used a NT2 selective inhibitor to confirm this. Phasic and tonic
Neurotensin induced changes with and without the mucosa intact were significantly inhibited by
the NT2 selective inhibitor. As with the other antagonists, the selective NT2 antagonist had no
effect on basal phasic activity or basal tone when added alone. This confirms the notion that
there is no basal, unstimulated release of Neurotensin that is modifying the basal contractile
activity of the colonic muscle.
The findings of the selective NT2 receptor antagonist, in conjunction with the findings
with the non-selective inhibitor, supports the idea that the effects of Neurotensin on the rat distal
colon are mediated by the NT2 receptor. The results with the non-selective antagonists are
particularly important because if there were other receptors outside of these receptors, the
nonselective receptor inhibitor would likely not have abolished all the effects of Neurotensin that
were observed. One factor we considered as a confounding influence was the sortilin receptor,
also known as the NT3 receptor, since it binds Neurotensin. In studies in a variety of tissues, this
NT3/sortilin receptor has been found to make multimers with other receptors such as the TrkB
receptor to change its affinity or selectivity (Nykjaer 2012). The NT3/sortilin receptor has
normally been thought of in this way or as a clearance receptor because it does not couple to a
signaling pathway in most tissues. Only very recently, have reports begun to suggest that in some
tissues there is a more complex role of the NT3/sortilin receptor. Considering that there is no
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specific antagonist of this receptor, the current thinking that this is a non-signaling receptor, and
the strong effects of the NT2 selective and the NT1-NT2 nonselective antagonist, we concluded
that the effects of Neurotensin we observed were mediated by the NT2 receptor.
It is also important to note that there have been doubts cast regarding the agonistic
properties of Neurotensin at this site and subsequently, doubts as to whether this receptor can be
truly regarded as a true Neurotensin receptor (Gendron 2004). In CHO cells stably transfected
with human NT2 receptor, SR48692, but neither Neurotensin nor levocabastine, was found to
activate classic second messenger systems, such as phosphoinositide hydrolysis, Ca

2+

mobilization, or ERK1/2 phosphorylation. (Vita et al 1998) (Richard et al 2001). This would
suggest that the Neurotensin receptor either itself differs somehow in function from the same
receptor found in rodents, or is mediated through different signaling mechanisms. With the
possibility that rodent NT2 receptors function differently than human receptor, our findings
support this idea.

4.6 Existence of the NT2 Receptor
To confirm the physiological and pharmacological evidence for the action and presence
of an NT2 receptor in the rat distal colon, we turned to a molecular approach. Western Blot
results indicate that the NT2 receptor was found in the mucosa, the muscle, and in the intact
distal rat colon. With the receptor located in both the muscle and the mucosa, it makes sense that
regardless whether the mucosa was intact or not, an effect was observed. Previous studies have
suggested that the NT2 receptor is absent in the colon of rats (Pettibone 2002) but our results
contradict those claims. Other studies claim that the NT2 receptor is scarcely found in the
periphery but not necessarily absent. It is possible that the rat colon is unique in that the NT2
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receptor is found there and not in other species, but this would require further studies to be done.
At the very least, the finding of the NT2 receptor helps strengthen the argument that the NT2
receptor exists in the distal rat colon and plays an important role in the effects of Neurotensin on
phasic and tonic contraction. The Western Blot also included samples of the proximal rat colon
where the NT1 and NT2 receptors were already previously found to exist. This was done to
confirm the validity of the antibody and shows that the NT2 receptor exists in both sections of
the colon.
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4.7 Avenues to Explore
To further and strengthen the model, the following experiments are proposed:
•

Downstream mediators of the NT1 and NT2 receptor have been identified in other models and
must be confirmed to in the rat distal colon

•

If Neurotensin does in fact lead to further excitatory or inhibitory neurotransmitter release, the
identification of these should be explored

•

Muscarinic antagonism and Na+ channel blockade by TTX to determine neural contributions and
possible modulation by M2 signaling
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